Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...
100 College Road West
Princeton, NJ 08540
Founded in 1946
Sandoz Inc. Wins $6.42 Million Federal Contract
Jul 14 17
Sandoz Inc. has won a $6,421,953.20 federal contract modification from the U.S. Department of Veterans Affairs for perphenazine tablets.
Sandoz Inc. Wins $13.85 Million Federal Contract
May 26 17
Sandoz Inc. won a $13,845,180 federal contract from the Defense Logistics Agency for rivastigmine patches.
Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. Partially Settle Class Action Lawsuit Involving the Antibiotic Drug Solodyn
Apr 28 17
Partial settlements have been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (Defendants) violated state competition (antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective. To settle the lawsuit, Lupin Pharmaceuticals Inc. and Lupin Limited (Lupin Defendants) and Sandoz Inc. have each agreed: that they would be willing to provide certain witnesses that Plaintiffs could call and a declaration that the Plaintiffs could use during the Solodyn case involving the overall End-Payor Class, other Plaintiffs, and the Non-Settling Defendants; and to deposit $625,000 and $1.75 million, respectively, into Settlement Funds. If the Settlements are approved by the Court and become final, the Settlement Funds, inclusive of interest, will be used to: pay for costs and expenses incurred or to be incurred by Counsel in continuing the lawsuit against Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., and Impax Laboratories, Inc. (Non-Settling Defendants); cover taxable costs and taxes payable on the Settlement Funds; pay for notice and other expenses; and pay for service awards not to exceed $10,000 to the class representatives in recognition of their efforts to date on behalf of the Classes. Any remainder in the Settlement Funds, after the payment of the above expenses, shall be distributed to the End-Payor Class for the Lupin Settlement and the End-Payor Class for the Sandoz Settlement in a manner approved by the court at the conclusion of the litigation. These settlements involve only the Lupin Defendants and Sandoz. The case will continue against the non-settling defendants.